Inhibitor Therapeutics Inc
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal… Read more
Inhibitor Therapeutics Inc (INTI) - Net Assets
Latest net assets as of September 2025: $3.45K USD
Based on the latest financial reports, Inhibitor Therapeutics Inc (INTI) has net assets worth $3.45K USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.14 Million) and total liabilities ($3.13 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.45K |
| % of Total Assets | 0.11% |
| Annual Growth Rate | 18.71% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3106.01 |
Inhibitor Therapeutics Inc - Net Assets Trend (2015–2024)
This chart illustrates how Inhibitor Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Inhibitor Therapeutics Inc (2015–2024)
The table below shows the annual net assets of Inhibitor Therapeutics Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.99 Million | -62.43% |
| 2023-12-31 | $5.28 Million | -36.31% |
| 2022-12-31 | $8.30 Million | +329.13% |
| 2021-12-31 | $-3.62 Million | -7.76% |
| 2020-12-31 | $-3.36 Million | -32.75% |
| 2019-12-31 | $-2.53 Million | -7923.98% |
| 2018-12-31 | $32.35K | -80.58% |
| 2017-12-31 | $166.56K | -97.63% |
| 2016-12-31 | $7.03 Million | +1558.09% |
| 2015-12-31 | $423.98K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Inhibitor Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1594671900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $54.10 Million | 2725.60% |
| Total Equity | $1.99 Million | 100.00% |
Inhibitor Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Inhibitor Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
HOCHDORF HLDG AG
F:1Z3
|
$3.93 Million |
|
SUNMIRROR AG SF 1
F:ROR
|
$3.93 Million |
|
McLaren Resources Inc
F:3ML
|
$3.94 Million |
|
BOCANA RESOURCES CORP.
F:VC1
|
$3.94 Million |
|
Merida Minerals Inc.
V:ESPN
|
$3.93 Million |
|
Grand Gulf Energy Ltd
AU:GGE
|
$3.93 Million |
|
Planet Ventures Inc
PINK:PNXPF
|
$3.93 Million |
|
Beam Communications Holdings Ltd
AU:BCC
|
$3.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Inhibitor Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,283,991 to 1,985,040, a change of -3,298,951 (-62.4%).
- Net loss of 3,339,201 reduced equity.
- Other factors increased equity by 40,250.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.34 Million | -168.22% |
| Other Changes | $40.25K | +2.03% |
| Total Change | $- | -62.43% |
Book Value vs Market Value Analysis
This analysis compares Inhibitor Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 113.17x to 4.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.00 | $0.05 | x |
| 2018-12-31 | $0.00 | $0.05 | x |
| 2019-12-31 | $-0.01 | $0.05 | x |
| 2020-12-31 | $-0.01 | $0.05 | x |
| 2021-12-31 | $-0.01 | $0.05 | x |
| 2022-12-31 | $0.05 | $0.05 | x |
| 2023-12-31 | $0.03 | $0.05 | x |
| 2024-12-31 | $0.01 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Inhibitor Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -168.22%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.87x
- Recent ROE (-168.22%) is above the historical average (-1823.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -931.55% | 0.00% | 0.00x | 2.09x | $-3.99 Million |
| 2016 | -99.58% | 0.00% | 0.00x | 1.04x | $-7.70 Million |
| 2017 | -3062.60% | 0.00% | 0.00x | 4.61x | $-5.12 Million |
| 2018 | -14065.19% | 0.00% | 0.00x | 38.11x | $-4.55 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.48 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-721.91K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $63.45K |
| 2022 | 145.92% | 0.00% | 0.00x | 1.44x | $11.28 Million |
| 2023 | -57.27% | 0.00% | 0.00x | 1.69x | $-3.55 Million |
| 2024 | -168.22% | 0.00% | 0.00x | 2.87x | $-3.54 Million |
Industry Comparison
This section compares Inhibitor Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Inhibitor Therapeutics Inc (INTI) | $3.45K | -931.55% | 906.95x | $3.93 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |